Edwards Lifesciences (NYSE:EW) Given "Hold (C)" Rating at Weiss Ratings

Key Points

• Edwards Lifesciences' stock has been given a "hold (C)" rating by Weiss Ratings, reflecting a cautious outlook amidst mixed recommendations from other analysts.
• The company reported a quarterly earnings of $0.67 per share, exceeding analysts' estimates, and showed an 11.9% increase in revenue year-over-year, totaling $1.53 billion.
• Edwards Lifesciences has a consensus target price of $87.06 and is currently rated as a "Moderate Buy" by market analysts.

Edwards Lifesciences (NYSE:EW - Get Free Report)'s stock had its "hold (c)" rating reiterated by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Several other research firms have also commented on EW. JPMorgan Chase & Co. upped their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, July 25th. Stifel Nicolaus set a $85.00 target price on Edwards Lifesciences and gave the company a "buy" rating in a research note on Monday, September 22nd. BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price for the company in a research note on Tuesday, July 29th. Oppenheimer lowered Edwards Lifesciences from an "outperform" rating to a "market perform" rating in a research note on Wednesday. Finally, Evercore ISI set a $88.00 target price on Edwards Lifesciences and gave the company an "outperform" rating in a research note on Tuesday. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $87.06.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded down $0.97 during trading on Wednesday, reaching $75.75. The company had a trading volume of 5,601,035 shares, compared to its average volume of 4,871,276. Edwards Lifesciences has a twelve month low of $64.89 and a twelve month high of $83.00. The stock has a market capitalization of $44.47 billion, a PE ratio of 10.90, a price-to-earnings-growth ratio of 3.69 and a beta of 1.05. The stock has a 50-day moving average price of $78.28 and a two-hundred day moving average price of $76.05. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. During the same period in the previous year, the firm posted $0.70 earnings per share. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Wedmont Private Capital lifted its holdings in Edwards Lifesciences by 3.8% during the 3rd quarter. Wedmont Private Capital now owns 12,545 shares of the medical research company's stock worth $962,000 after buying an additional 455 shares during the last quarter. Czech National Bank lifted its holdings in Edwards Lifesciences by 4.0% during the 3rd quarter. Czech National Bank now owns 149,112 shares of the medical research company's stock worth $11,596,000 after buying an additional 5,727 shares during the last quarter. Orser Capital Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth approximately $2,174,000. Cullen Investment Group LTD. lifted its holdings in Edwards Lifesciences by 2.2% during the 3rd quarter. Cullen Investment Group LTD. now owns 22,234 shares of the medical research company's stock worth $1,714,000 after buying an additional 483 shares during the last quarter. Finally, Sanders Morris Harris LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $313,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.